Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
$12.75
-3.0%
$14.45
$8.20
▼
$23.40
$52.03M-1918.6925,654 shs32,673 shs
Rafael Holdings, Inc. stock logo
RFL
Rafael
$0.98
-8.7%
$1.54
$0.97
▼
$3.96
$57.92M0.7563,797 shs74,717 shs
Scilex Holding Company stock logo
SCLX
Scilex
$1.25
-12.6%
$3.32
$1.24
▼
$27.00
$13.25M1.8539,506 shs90,572 shs
Talphera, Inc. stock logo
TLPH
Talphera
$0.86
-5.0%
$1.10
$0.69
▼
$1.57
$53.72M0.7785,095 shs348,630 shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
0.00%+5.71%+0.92%-28.80%+∞
Rafael Holdings, Inc. stock logo
RFL
Rafael
0.00%+3.98%-22.07%-42.78%-13.71%
Scilex Holding Company stock logo
SCLX
Scilex
0.00%-15.88%-49.47%-77.66%-91.92%
Talphera, Inc. stock logo
TLPH
Talphera
0.00%-13.71%-16.11%-24.50%-27.52%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
$12.75
-3.0%
$14.45
$8.20
▼
$23.40
$52.03M-1918.6925,654 shs32,673 shs
Rafael Holdings, Inc. stock logo
RFL
Rafael
$0.98
-8.7%
$1.54
$0.97
▼
$3.96
$57.92M0.7563,797 shs74,717 shs
Scilex Holding Company stock logo
SCLX
Scilex
$1.25
-12.6%
$3.32
$1.24
▼
$27.00
$13.25M1.8539,506 shs90,572 shs
Talphera, Inc. stock logo
TLPH
Talphera
$0.86
-5.0%
$1.10
$0.69
▼
$1.57
$53.72M0.7785,095 shs348,630 shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
0.00%+5.71%+0.92%-28.80%+∞
Rafael Holdings, Inc. stock logo
RFL
Rafael
0.00%+3.98%-22.07%-42.78%-13.71%
Scilex Holding Company stock logo
SCLX
Scilex
0.00%-15.88%-49.47%-77.66%-91.92%
Talphera, Inc. stock logo
TLPH
Talphera
0.00%-13.71%-16.11%-24.50%-27.52%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
2.86
Moderate Buy$37.33192.81% Upside
Rafael Holdings, Inc. stock logo
RFL
Rafael
1.00
SellN/AN/A
Scilex Holding Company stock logo
SCLX
Scilex
1.00
SellN/AN/A
Talphera, Inc. stock logo
TLPH
Talphera
2.25
Hold$3.00248.47% Upside

Current Analyst Ratings Breakdown

Latest SCLX, TLPH, RFL, and ELOX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/28/2026
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
Lower Price TargetBuy$43.00 ➝ $40.00
10/16/2026
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
UpgradeHold
10/15/2026
Talphera, Inc. stock logo
TLPH
Talphera
Reiterated RatingSell (D-)
10/15/2026
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
Initiated CoverageOverweight
9/18/2026
Scilex Holding Company stock logo
SCLX
Scilex
DowngradeSell (D-) ➝ Sell (E+)
9/18/2026
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
Set Price TargetOutperform$32.00
9/18/2026
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
UpgradeStrong-Buy$32.00
9/2/2026
Scilex Holding Company stock logo
SCLX
Scilex
UpgradeSell (E+) ➝ Sell (D-)
8/25/2026
Rafael Holdings, Inc. stock logo
RFL
Rafael
Reiterated RatingSell (D-)
8/24/2026
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
Reiterated RatingBuy$43.00
8/20/2026
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
UpgradeStrong-Buy
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
$6.36M8.10N/AN/A($85.17) per share-0.15
Rafael Holdings, Inc. stock logo
RFL
Rafael
$870K58.61N/AN/A$1.38 per share0.71
Scilex Holding Company stock logo
SCLX
Scilex
$30.25M0.35N/AN/A($24.94) per share-0.05
Talphera, Inc. stock logo
TLPH
Talphera
$30K1,489.64N/AN/A$0.37 per share2.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
-$5.99M-$1.54N/AN/AN/AN/AN/AN/AN/A
Rafael Holdings, Inc. stock logo
RFL
Rafael
-$29.64M-$0.58N/AN/AN/A-3,390.73%-41.03%-35.14%12/10/2026 (Estimated)
Scilex Holding Company stock logo
SCLX
Scilex
-$358.73M-$49.70N/AN/AN/A-1,414.57%N/A-147.00%12/2/2026 (Estimated)
Talphera, Inc. stock logo
TLPH
Talphera
-$14.29M-$0.21N/AN/AN/AN/A-88.09%-50.73%N/A

Latest SCLX, TLPH, RFL, and ELOX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
12/2/2026Q3 2026
Scilex Holding Company stock logo
SCLX
Scilex
-$0.0756N/AN/AN/A$17.00 millionN/A
11/13/2026Q3 2026
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
N/A-$0.49N/A-$0.49N/AN/A
11/12/2026Q3 2026
Talphera, Inc. stock logo
TLPH
Talphera
-$0.05-$0.05N/A-$0.05N/AN/A
10/29/2026Q4 2026
Rafael Holdings, Inc. stock logo
RFL
Rafael
N/A-$0.18N/A-$0.18N/A$0.24 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
N/AN/AN/AN/AN/A
Rafael Holdings, Inc. stock logo
RFL
Rafael
N/AN/AN/AN/AN/A
Scilex Holding Company stock logo
SCLX
Scilex
N/AN/AN/AN/AN/A
Talphera, Inc. stock logo
TLPH
Talphera
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
N/A
3.74
3.74
Rafael Holdings, Inc. stock logo
RFL
Rafael
N/A
2.35
2.32
Scilex Holding Company stock logo
SCLX
Scilex
N/A
0.07
0.06
Talphera, Inc. stock logo
TLPH
Talphera
N/A
4.29
4.29

Institutional Ownership

CompanyInstitutional Ownership
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
2.90%
Rafael Holdings, Inc. stock logo
RFL
Rafael
11.30%
Scilex Holding Company stock logo
SCLX
Scilex
69.67%
Talphera, Inc. stock logo
TLPH
Talphera
37.67%

Insider Ownership

CompanyInsider Ownership
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
25.90%
Rafael Holdings, Inc. stock logo
RFL
Rafael
32.90%
Scilex Holding Company stock logo
SCLX
Scilex
4.50%
Talphera, Inc. stock logo
TLPH
Talphera
3.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Eloxx Pharmaceuticals, Inc. stock logo
ELOX
Eloxx Pharmaceuticals
74.04 million2.99 millionN/A
Rafael Holdings, Inc. stock logo
RFL
Rafael
1752.19 million35.02 millionOptionable
Scilex Holding Company stock logo
SCLX
Scilex
348.49 million8.11 millionNo Data
Talphera, Inc. stock logo
TLPH
Talphera
1251.91 million50.09 millionOptionable

Recent News About These Companies

Talphera (TLPH) Q3 2026 Earnings Call Transcript
What Talphera (TLPH) Said on Its Q3 Earnings Call
Talphera, Inc. (TLPH) Q3 2026 Earnings Call Transcript
Talphera (NASDAQ:TLPH) Issues Earnings Results
Talphera (TLPH) Expected to Release Quarterly Earnings on Thursday
Talphera (TLPH) Stock Forecast & Price Target
Talphera (TLPH) Q2 2026 Earnings Call Transcript
Talphera, Inc. (TLPH) Q2 FY2026 earnings call transcript
Talphera, Inc. (TLPH) Stock Major Holders - Yahoo Finance
Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript
Talphera Q2 2026 earnings preview

New MarketBeat Followers Over Time

Media Sentiment Over Time

Eloxx Pharmaceuticals stock logo

Eloxx Pharmaceuticals NASDAQ:ELOX

$12.75 -0.40 (-3.04%)
As of 04:00 PM Eastern

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company's lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.

Rafael stock logo

Rafael NYSE:RFL

$0.98 -0.09 (-8.69%)
Closing price 03:59 PM Eastern
Extended Trading
$0.98 +0.00 (+0.41%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Scilex stock logo

Scilex NASDAQ:SCLX

$1.25 -0.18 (-12.59%)
Closing price 04:00 PM Eastern
Extended Trading
$1.25 +0.00 (+0.40%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

Talphera stock logo

Talphera NASDAQ:TLPH

$0.86 -0.05 (-4.98%)
Closing price 04:00 PM Eastern
Extended Trading
$0.86 +0.00 (+0.01%)
As of 05:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.